Alembic Pharmaceuticals Secures USFDA Approval for Otic Suspension Targeting $110 Million Market

Key numbers

Market Cap	₹15,517.67 CrMid-cap Pharma
P/E TTM	22.38Sector PE 45.17
Revenue Growth	25.66%YoY (Q1 FY27)
Promoter Holding	69.87%Latest Quarter

Key highlights

• USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%
• Estimated market size of US$110 million for the twelve months ending June 2026
• Cumulative USFDA ANDA approvals reached 246, including 226 final approvals
• Therapeutically equivalent to Sandoz Inc. reference drug product Ciprodex
• Approved for treating Acute Otitis Media and Acute Otitis Externa in pediatric and adult patients

Strategic Expansion into Specialised Generic Formulations

Alembic Pharmaceuticals has reached a significant regulatory milestone with the USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. This approval allows the company to manufacture and market a generic version of Ciprodex Otic Suspension, a critical treatment for middle and outer ear infections. The approval targets a substantial commercial opportunity, as IQVIA data estimates the market size for this suspension at approximately US$110 million for the trailing twelve-month period ending June 2026.

This development follows a series of regulatory successes, including recent final approvals for Prucalopride tablets in July 2026 and Dapsone gel in June 2026, further diversifying the company's export portfolio.

Indications and Product Portfolio Status

• The approved ANDA is therapeutically equivalent to the reference listed drug product Ciprodex Otic Suspension from Sandoz Inc.
• Indicated for Acute Otitis Media in pediatric patients aged 6 months and older with tympanostomy tubes.
• Authorized for treating Acute Otitis Externa in pediatric, adult, and elderly patient populations.
• Alembic now holds 246 cumulative ANDA approvals, comprising 226 final and 20 tentative approvals from USFDA.
• This approval supports management's plan to execute 15 or more product launches slated for the 2027 fiscal year.

Operational Strength and Mid-Teen Revenue Guidance

The company's latest financial results for the quarter ended June 30, 2026, demonstrate strong operational momentum, with operating revenue reaching ₹2,149.77 crore. This represents a 25.66% year-on-year increase, significantly outperforming the sector revenue growth of 15.55%. In August 2026, Alembic management upgraded its full-year revenue growth guidance for FY27 to the mid-teen range, driven by expected mid-to-high teen growth in the US generics segment.

This regulatory approval aligns with those growth targets and follows the issuance of an Establishment Inspection Report for the company’s Bioequivalence Facility at Vadodara in September 2026, signaling sustained compliance at its research sites.

What to watch next

• Statutory SEBI reporting deadline for Q2 FY27 unaudited financial results on 14 November 2026
• Commercial launch and market penetration progress of the newly approved Otic Suspension
• Regulatory updates on the remaining 33 pending ANDA filings from the cumulative 279 filings

Alembic Pharmaceuticals · financial snapshot

Share price	₹789.45
Market capitalisation	₹15,517.67 Cr
Revenue (annual)	₹7,344.90 Cr
Net profit (annual)	₹674.77 Cr
Revenue (latest quarter)	₹2,149.77 Cr+16.35% vs previous quarter
Net profit (latest quarter)	₹173.07 Cr-14.62% vs previous quarter
P/E (TTM)	22.38×Sector 45.17×
Promoter holding	69.87%+0.13% QoQ
FII holding	4.17%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.